Clinical reference Biomarker Directory
Back to directory

CHGA

Established

CgA is the most widely used general biomarker for neuroendocrine tumors, though prone to false elevation.

Also known as CgA chromogranin A
In plain language

Chromogranin A is the most common blood test for neuroendocrine tumors, but common acid-reflux medications can falsely raise it, sometimes leading to unnecessary cancer workups. Doctors need to rule out these other causes before relying on a high result.

Biomarker & context

Chromogranin A (CgA) is a protein co-stored and released with hormones in neuroendocrine cells throughout the body, making it the most widely used general biomarker for neuroendocrine tumors (NETs).

What it indicates

CgA levels correlate with neuroendocrine tumor burden and are used for diagnosis, monitoring treatment response, and detecting recurrence, but the marker has real non-specificity problems that limit its standalone reliability.

Diagnosis & clinical testing

Measured via serum immunoassay; sensitivity and specificity are approximately 75% and 84% respectively. Proton pump inhibitors, atrophic gastritis, and impaired kidney function can all falsely elevate CgA, sometimes 5-20x above normal, and there is documented case literature of patients undergoing unnecessary NET workups because of PPI-related false elevation.

Guiding treatment

Before attributing an elevated CgA to a neuroendocrine tumor, clinicians should confirm the patient is not on a PPI or has another explanation for false elevation; newer multi-gene blood signatures are being explored as more specific alternatives, though none has yet definitively replaced CgA.

Clinical significance

Real risk of false-positive elevation from proton pump inhibitors and other benign conditions.

References
  1. PMC. (2016). Chromogranin A - unspecific neuroendocrine marker: Clinical utility and potential diagnostic pitfalls.
  2. Cureus. (2023). Ten-Fold Elevation of Chromogranin A Level Unrelated to a Neuroendocrine Tumor: Diagnostic Interference of PPIs.